At a glance
ClinicalIndex Comparison RecordPhase 3Active· 25 enrolled
Drug / intervention
Anamorelin Hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Qualitative Study on Experiences Related to Anorexia and the Effects of Anamorelin and Placebo in Advanced Non-Small-Cell Lung Cancer Patients With Anorexia-Cachexia: A Preliminary Study
In Brief
A Phase 3 clinical trial evaluating Anamorelin Hydrochloride, Placebo, and 1 other intervention for Anorexia and 8 related conditions. Active but no longer recruiting, targeting 25 participants across 1 site.
Detailed Summary
This phase II/III trial studies how well anamorelin hydrochloride works in reducing anorexia in patients with non-small cell lung cancer that has spread to other places in the body. Anamorelin hydrochloride may help to improve patients' appetite in order to stop weight loss.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia, Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 3Active
201920202021202220232024202520262027
First PostedAug 2018
Enrollment StartNov 2018
TodayJul 2026
Primary CompletionDec 2026
First PostedAug 20, 2018
Enrollment StartNov 27, 2018
Primary CompletionDec 31, 2026
TodayJul 1, 2026
Enrollment to primary: 8.1 yearsPosted 7.9 years agoPrimary completion in 6 months
Interventions
Anamorelin Hydrochloridedrug
Given PO
Placeboother
Given PO
Questionnaire Administrationother
Ancillary studies